Zydus Cadila has received the final approval from the USFDA to market Carboplatin Injection, 10 mg/ml in 5 ml, 15 ml and 45 ml. The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
